Summary

Eligibility
for people ages 18-75 (full criteria)
Location
at UCSF
Dates
study started
estimated completion

Description

Summary

This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.

Official Title

A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF-06650833, PF-06700841, AND PF-06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA

Keywords

Acne Inversa Hidradenitis Suppurativa Hidradenitis

Eligibility

You can join if…

Open to people ages 18-75

  • male or female participants, between 18-75, with a diagnosis of moderate to severe Hidradenitis Suppurativa

You CAN'T join if...

  • History of human immunodeficiency virus (HIV) or positive HIV serology at screening,
  • Infected with hepatitis B or hepatitis C viruses.
  • Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)

Locations

  • UCSF Dermatology Clinic not yet accepting patients
    San Francisco California 94115 United States
  • University of California San Francisco not yet accepting patients
    San Francisco California 94115 United States
  • UCSF Psoriasis and Skin Treatment Center not yet accepting patients
    San Francisco California 94118 United States
  • Clinical Science Institute accepting new patients
    Santa Monica California 90404 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Pfizer
ID
NCT04092452
Phase
Phase 2
Study Type
Interventional
Last Updated